Clinical Trials
71 trialsCeritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
NRG Oncology
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
COD
National Cancer Institute (NCI)
SABR-COMET-3
British Columbia Cancer Agency
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
TROPiCS-03
Gilead Sciences
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Shanghai Changzheng Hospital
COBRA: Cancer, Older Adults, Balance and Resistance Activities
Memorial Sloan Kettering Cancer Center
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
M.D. Anderson Cancer Center
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
SAFFRON
AstraZeneca
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DPT01
AstraZeneca
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
MTRON
AO Innovation Translation Center
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Cryoablation for the Treatment of Metastatic Cancer
M.D. Anderson Cancer Center
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
University of Rochester
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
PLUMMB
Royal Marsden NHS Foundation Trust
Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
SOUND
Medical University of Graz
SERENA-2
AstraZeneca
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
British Columbia Cancer Agency
SABR-COMET 10
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
HER2-PREDICT
SOLTI Breast Cancer Research Group